LLY

1,015.9

+0.19%↑

JNJ

242.84

-1.14%↓

ABBV

225.52

+0.67%↑

NVS

163.02

-0.01%↓

MRK

121.76

+0.26%↑

LLY

1,015.9

+0.19%↑

JNJ

242.84

-1.14%↓

ABBV

225.52

+0.67%↑

NVS

163.02

-0.01%↓

MRK

121.76

+0.26%↑

LLY

1,015.9

+0.19%↑

JNJ

242.84

-1.14%↓

ABBV

225.52

+0.67%↑

NVS

163.02

-0.01%↓

MRK

121.76

+0.26%↑

LLY

1,015.9

+0.19%↑

JNJ

242.84

-1.14%↓

ABBV

225.52

+0.67%↑

NVS

163.02

-0.01%↓

MRK

121.76

+0.26%↑

LLY

1,015.9

+0.19%↑

JNJ

242.84

-1.14%↓

ABBV

225.52

+0.67%↑

NVS

163.02

-0.01%↓

MRK

121.76

+0.26%↑

Search

Twist Bioscience Corp

Открыт

СекторЗдравоохранение

50 -5.66

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

50

Макс.

53.26

Ключевые показатели

By Trading Economics

Доход

-3.4M

-31M

Продажи

4.7M

104M

Рентабельность продаж

-29.419

Сотрудники

979

EBITDA

-3.2M

-24M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

-5.32% downside

Дивиденды

By Dow Jones

Следующий отчет о доходах

4 мая 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

409M

3B

Предыдущая цена открытия

55.66

Предыдущая цена закрытия

50

Новостные настроения

By Acuity

50%

50%

162 / 351 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Twist Bioscience Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

19 февр. 2026 г., 23:47 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

19 февр. 2026 г., 23:47 UTC

Обсуждения рынка

Nikkei May Decline Amid Caution Over Potential U.S. Strike on Iran -- Market Talk

19 февр. 2026 г., 23:39 UTC

Приобретения, слияния, поглощения

Swiss Re Corporate Solutions to Buy QBE Insurance's Global Trade Credit and Surety Business >SREN.EB

19 февр. 2026 г., 23:38 UTC

Отчет

Samsung Fire & Marine Insurance 2025 Net KRW2.020T Vs. Net KRW2.077T >000810.SE

19 февр. 2026 г., 23:38 UTC

Отчет

Samsung Fire & Marine Insurance 2025 Oper Pft KRW2.659T Vs. Pft KRW2.650T >000810.SE

19 февр. 2026 г., 23:38 UTC

Отчет

Samsung Fire & Marine Insurance 2025 Rev KRW24.779T Vs. KRW22.657T >000810.SE

19 февр. 2026 г., 23:37 UTC

Обсуждения рынка

Gold Edges Lower on Possible Position Adjustment -- Market Talk

19 февр. 2026 г., 23:34 UTC

Отчет

Samsung Fire & Marine Insurance 4Q Net Profit Missed FactSet-Compiled Consensus

19 февр. 2026 г., 23:34 UTC

Отчет

Samsung Fire & Marine Insurance 4Q Net KRW234.38B Vs. Net KRW207.88B >000810.SE

19 февр. 2026 г., 23:33 UTC

Отчет

Samsung Fire & Marine Insurance 4Q Oper Pft KRW391.26B Vs. Pft KRW252.81B >000810.SE

19 февр. 2026 г., 23:33 UTC

Отчет

Samsung Fire & Marine Insurance 4Q Rev KRW6.083T Vs. KRW6.297T >000810.SE

19 февр. 2026 г., 22:13 UTC

Обсуждения рынка

Goodman's Lack of Earnings Upgrade 'Largely Timing Related' -- Market Talk

19 февр. 2026 г., 22:08 UTC

Отчет

Fairfax Financial 4Q Rev $8.11B >FFH.T

19 февр. 2026 г., 22:07 UTC

Отчет

Eldorado Gold 4Q EPS $1.19 >ELD.T

19 февр. 2026 г., 22:06 UTC

Отчет

Centerra Gold: 2026 Consolidated Gold Production Expected 250,000 to 280,000 Ounces, Copper Production Expected 50M to 60M Pounds >CG.T

19 февр. 2026 г., 22:05 UTC

Отчет

Eldorado Gold 4Q Adj EPS 63c >ELD.T

19 февр. 2026 г., 22:05 UTC

Отчет

Eldorado Gold 4Q Rev $577.2M >ELD.T

19 февр. 2026 г., 22:04 UTC

Отчет

Eldorado Gold 4Q Gold Sales 126,923 Ounces >ELD.T

19 февр. 2026 г., 22:04 UTC

Отчет

Eldorado Gold 4Q Gold Production 123,416 Ounces >ELD.T

19 февр. 2026 г., 21:50 UTC

Обсуждения рынка
Отчет

Tech, Media & Telecom Roundup: Market Talk

19 февр. 2026 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

19 февр. 2026 г., 21:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

19 февр. 2026 г., 21:43 UTC

Отчет

St Barbara 1H Underlying Profit A$1.3 Million Vs A$48.1 Million Loss Year Earlier

19 февр. 2026 г., 21:42 UTC

Приобретения, слияния, поглощения

Palo Alto Networks Announces Offer to Purchase Relating to CyberArk Software Ltd.'s 0.00% Convertible Senior Notes Due 2030

19 февр. 2026 г., 21:42 UTC

Отчет

St Barbara 1H Revenue A$128.8 Million, Up 32% On-Year

19 февр. 2026 г., 21:41 UTC

Отчет

Correct: St Barbara 1H Net Loss A$249,000

19 февр. 2026 г., 21:40 UTC

Отчет

St Barbara 1H Net Loss A$249 Million

19 февр. 2026 г., 21:39 UTC

Отчет

Perseus Mining Reaffirms FY26 Production, AISC Guidance

19 февр. 2026 г., 21:37 UTC

Отчет

These Stocks Are Today's Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and More -- Barrons.com

19 февр. 2026 г., 21:37 UTC

Отчет

Century Aluminum Expects 1Q Adj EBITDA $215 M to $235 M >CENX

Сравнение c конкурентами

Изменение цены

Twist Bioscience Corp Прогноз

Целевая цена

By TipRanks

-5.32% падение

Прогноз на 12 месяцев

Средняя 52 USD  -5.32%

Максимум 58 USD

Минимум 50 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Twist Bioscience Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

6 ratings

6

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

31.56 / 38.6884Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

162 / 351Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat